East Tennessee State University

Digital Commons @ East Tennessee State University
ETSU Faculty Works

Faculty Works

1-28-2014

Design and Optimization of PLGA-Based Diclofenac Loaded
Nanoparticles
Dustin L. Cooper
East Tennessee State University

Sam Harirforoosh
East Tennessee State University, harirfor@etsu.edu

Follow this and additional works at: https://dc.etsu.edu/etsu-works

Citation Information
Cooper, Dustin L.; and Harirforoosh, Sam. 2014. Design and Optimization of PLGA-Based Diclofenac
Loaded Nanoparticles. PLoS ONE. Vol.9(1). https://doi.org/10.1371/journal.pone.0087326 PMID:
24489896

This Article is brought to you for free and open access by the Faculty Works at Digital Commons @ East Tennessee
State University. It has been accepted for inclusion in ETSU Faculty Works by an authorized administrator of Digital
Commons @ East Tennessee State University. For more information, please contact digilib@etsu.edu.

Design and Optimization of PLGA-Based Diclofenac Loaded Nanoparticles
Copyright Statement
Copyright: ß 2014 Cooper, Harirforoosh. This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original author and source are credited.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This article is available at Digital Commons @ East Tennessee State University: https://dc.etsu.edu/etsu-works/
15732

Design and Optimization of PLGA-Based Diclofenac
Loaded Nanoparticles
Dustin L. Cooper, Sam Harirforoosh*
Department of Pharmaceutical Sciences, Gatton College of Pharmacy, East Tennessee State University, Johnson City, Tennessee, United States of America

Abstract
Drug based nanoparticle (NP) formulations have gained considerable attention over the past decade for their use in various
drug formulations. NPs have been shown to increase bioavailability, decrease side effects of highly toxic drugs, and prolong
drug release. Nonsteroidal anti-inflammatory drugs such as diclofenac block cyclooxygenase expression and reduce
prostaglandin synthesis, which can lead to several side effects such as gastrointestinal bleeding and renal insufficiency. The
aim of this study was to formulate and characterize diclofenac entrapped poly(lactide-co-glycolide) (PLGA) based
nanoparticles. Nanoparticles were formulated using an emulsion-diffusion-evaporation technique with varying concentrations of poly vinyl alcohol (PVA) (0.1, 0.25, 0.5, or 1%) or didodecyldimethylammonium bromide (DMAB) (0.1, 0.25, 0.5, 0.75,
or 1%) stabilizers centrifuged at 8,800 rpm or 12,000 rpm. The resultant nanoparticles were evaluated based on particle size,
zeta potential, and entrapment efficacy. DMAB formulated NPs showed the lowest particle size (10862.1 nm) and highest
zeta potential (227.7160.6 mV) at 0.1 and 0.25% respectively, after centrifugation at 12,000 rpm. Results of the PVA based
NP formulation showed the smallest particle size (92.467.6 nm) and highest zeta potential (211.1460.5 mV) at 0.25% and
1% w/v, respectively, after centrifugation at 12,000 rpm. Drug entrapment reached 77.363.5% and 80.261.2% efficiency
with DMAB and PVA formulations, respectively. The results of our study indicate the use of DMAB for increased nanoparticle
stability during formulation. Our study supports the effective utilization of PLGA based nanoparticle formulation for
diclofenac.
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side effects associated with various drugs when encapsulated into
polymer based nanoparticles and administered orally [5–7]. These
results demonstrate the effectiveness of nanoparticle formulation in
reducing and/or eliminating potential adverse side effects associate
with orally delivered toxic drugs.
Diclofenac nanoparticle reformulation has been used for
ophthalmic and transdermal delivery with promising results [8–
11]. The purpose of this study was to develop and characterize a
new oral formulation of diclofenac using polymer based nanoparticles. Nanoparticles were synthesized using a solvent-evaporation
technique and the effects of centrifugation speed and concentrations of two different stabilizers, poly (vinyl alcohol) (PVA) (Fig. 3)
or didodecyldimethylammonium bromide (DMAB) (Fig. 4), was
examined for effects on entrapment efficiency, particle size, and
stability.

Introduction
Over the past decade, there has been an increased interest in
particle manipulation and nanosizing of selected drugs. In
particular, polymeric nanoparticle formulation has gained an
increasing amount of public attention in the fields of drug delivery
and pharmaceutics. In recent years, the application of polymer
based nanoparticles in drug formulation has garnered immense
attention. Industry has focused, in large part, on the utilization of
biodegradable polymer based nanoparticles as effective drug
delivery agents because of their ability to prolong drug release,
increase drug bioavailability, decrease drug degradation and
reduce drug toxicity [1]. Research in nanoparticle drug formulations has focused heavily on the use of poly(lactic acid) (PLA),
poly(D,L glycolide) (PLG), and poly(lactide-co-glycolide) (PLGA)
(Fig. 1) based nanoparticles because of their tissue compatibility,
low toxicity, and high rate of hydrolysis [2].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the
most commonly prescribed drugs in the world [3]. NSAIDs are
pharmaceutical agents that exert analgesic and anti-inflammatory
effects through the inhibition of the cyclooxygenase family of
enzymes. Diclofenac is a NSAID that is commercially available in
its sodium (Fig. 2) or potassium salt form [4]. Like other NSAIDs,
common side effects associated with the use of diclofenac include
gastrointestinal lesion formation, and renal damage [4]. Interestingly, studies have shown a reduction in gastrointestinal and renal
PLOS ONE | www.plosone.org

Materials and Methods
Materials
PLGA (50:50 copolymer compositions; MW 30,000 Da),
didodecyldimethylammonium bromide (DMAB), poly vinyl alcohol (MW 89,000 Da) and 15 mL Corning centrifuge tubes were
purchased from Aldrich (St. Louis, MO, USA). Diclofenac was
obtained from MP Biomedical (Solon, OH, USA). Ethyl acetate
and high-performance liquidchromatography (HPLC)-grade water
were purchased from Fischer Scientific Laboratory (Fair Lawn,
1
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Figure 3. Chemical structure of poly vinyl alcohol (PVA) [47].
doi:10.1371/journal.pone.0087326.g003

stage centrifugation was calculated. Diclofenac stock solution
dissolved in methanol (200 mg/mL) was used to construct a
standard calibration curve (10,000 – 2,000,000 ng/mL). Pure
methanol was used as a blank experiment before UV measurement, after which total NP drug content was calculated using the
standard curve after control for blank NPs. Quantification was
performed by UV-spectrophotometry (Eppendorf Biophotometer,
Hauppauge, NY, USA) with absorbance set at 280 nm. Entrapment efficiency was calculated using the following equation:
Entrapment Efficiency = (Amount of diclofenac entrapped
within nanoparticles/Total amount of diclofenac used for synthesis) X 100

Figure 1. Chemical structure of poly (lactide-co-glycolide)
(PLGA) [45].
doi:10.1371/journal.pone.0087326.g001

NJ, USA). Phosphate buffer pH 7.0 was purchased from EMD
Chemicals Inc. (Gibbstown, NJ, USA). 0.2 micron syringe filters
were obtained from Millipore Corporation (Carrigtwohill, Ireland).

Method of nanoparticle preparation
Nanoparticles were prepared by an emulsion – diffusion –
evaporation technique [5] with slight modifications. Briefly, 45 mg
of diclofenac and 50 mg of PLGA were placed in 3 mL ethyl
acetate and stirred at 750 rpm for 30 minutes. Varying
concentrations of PVA (0.1, 0.25, 0.5, or 1% w/v) or DMAB
(0.1, 0.25, 0.5, 0.75, or 1% w/v) stabilizers were placed within
6 mL of HPLC grade water heated to 140uC and stirred at
750 rpm until fully dissolved. The organic phase was then added
to aqueous phase in a drop wise manner under moderate stirring
then sonicated for 5 minutes at 20 kHz using a sonic dismembrator (Fischer Scientific, Fair Lawn, NJ, USA). To facilitate
diffusion, 25 mL of water was added to each emulsion under
constant stirring at 750 rpm. Emulsions were stirred at 750 rpm
for 4 hours to insure complete organic phase evaporation. After
which, each emulsion was centrifuge (8,800 rpm or 12,000 rpm)
and supernatant was collected.

Effects of centrifugation speed and stabilizer
concentration on nanoparticle properties
NPs were formulated with five different concentrations of
DMAB (0.1, 0.25, 0.5, 0.75, or 1% w/v) and four different
concentrations of PVA (0.1, 0.25, 0.5, or 1% w/v). Effect of
stabilizer concentrations and two centrifugation rates (8,800 or
12,000 rpm) on zeta potential, particle size, and entrapment
efficiency was evaluated.

Nanoparticle morphology characterization
Shape and surface morphology of NPs were examined with a
transmission electron microscope (TEM) (Tecnai Philips Transmission Electron Microscope; FEI, Hillsboro, Oregon, USA). NP
solutions were vortex mixed and 2 mL of suspension was placed on
a 100 mesh copper grid covered with Formvar film (Electron
Microscopy Sciences, Hatfield, Pennsylvania). Samples were kept
under ventilation for 2 hours to allow for complete drying, than
examined by TEM at 80 kV.

Particle size and zeta potential
Particle size was measured by dynamic light scattering using a
Nicomp particle sizer (Particle Sizing Systems, Port Richy, FL,
USA). Zeta potential was estimated on the basis of electrophoretic
mobility under an electrical field. All measurements were
performed in triplicates.

In vitro drug release study
In vitro release of diclofenac sodium was carried out as previously
described with slight modification [12,13]. Briefly, 2 mL of
solution containing diclofenac formulated nanoparticles were
placed into 15 mL centrifuge tubes containing 8 mL phosphate
buffer. Suspensions were then placed on an electronic shaker set at
100 rpm. At various time points, 2 mL of release medium was
removed and replaced with the same volume of fresh medium.
Isolated samples were centrifuged at 4,400 rpm for 5 minutes and
filtered through a 0.2 micron syringe filter. Analysis was carried
out using a UV spectrophotometer set at 280 nm with empty
nanoparticle solutions used as control.

Entrapment efficiency
To measure the amount of diclofenac nanoparticle entrapment,
the amount of diclofenac present within solutions following end

Data treatment
Data is represented as mean 6 standard deviation (SD). The
unpaired Student’s t-test was used to analyze cumulative release
data for identical stabilizer concentrations.

Figure 4. Chemical structure of didodecyldimethylammonium
bromide (DMAB) [48].
doi:10.1371/journal.pone.0087326.g004

Figure 2. Chemical structure of diclofenac sodium [46].
doi:10.1371/journal.pone.0087326.g002
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Influence of centrifugation and DMAB stabilizer on
nanoparticle size and stability

Table 1. Method of nanoparticle preparation.

Ingredients
Organic phase

Aqueous phase

Emulsifier

Particle size and zeta potential measurements were conducted
using a NICOMP Zeta Sizer System with DMAB formulated
polymer NPs (Fig. 5). Measurements revealed low particle size and
increased zeta potential stability with low stabilizer concentrations.
Zeta potential reached peak measurements at 0.1 and 0.25%
DMAB concentration. A maximum zeta potential was reached at
227.760.6 mV using 0.25% DMAB formulation (Table 2).
Particle size was lowest using 0.1% DMAB concentrations and
highest at 0.5 and 0.75% DMAB concentrations (Table 2).
Interestingly, centrifugation speed was found to positively affect
stability and particle size. As centrifugation speed was increased
from 8,800 rpm to 12,000 rpm, there was a further increase in
zeta potential and decrease in particle size when compared to
lower centrifugation speed. Stability and particle size still followed
the same trends as seen in lower centrifugation speeds in relation
to stabilizer concentration with the exception of 0.25 and 0.5%,
which showed an increase in zeta potential and reduction in
particle size (Table 2).

Amount

PLGA

50 mg

Ethyl acetate

3 mL

Diclofenac

45 mg

DMAB

Variable1

PVA

Variable2

HPLC-grade water

6 mL

Sonic dismembrator

5 minutes (25 kHz)

1
DMAB concentrations varied 0.1, 0.25, 0.5, 0.75, and 1% w/v with respect to
solvent.
2
PVA concentrations varied 0.1, 0.25, 0.5, and 1% w/v with respect to solvent.
doi:10.1371/journal.pone.0087326.t001

Results
Synthesis and assembly of diclofenac loaded PLGA based
nanoparticles

Influence of centrifugation and PVA stabilizer on
nanoparticle size and stability

The synthesis of PLGA based nanoparticles was achieved
through an emulsion – diffusion – evaporation technique. A
solution of diclofenac and PLGA dissolved in ethyl acetate was
added to an aqueous solution containing stabilizer in a drop wise
manner, followed by sonication and moderate stirring for 4 hours
to ensure complete organic phase evaporation. The synthesis of
PLGA polymer based nanoparticles using ethyl acetate as the
primary solvent has been reported before [5,14,15]. In the present
study, PLGA NPs containing diclofenac were prepared using
DMAB and PVA as stabilizers. To determine optimal nanoparticle production, varying levels of DMAB and PVA stabilizer
concentration along with varying centrifugation speeds were
evaluated in the determination of peak nanoparticle synthesis
(Table 1). Aqueous to organic phase ratios of 1:1 were found to
elicit particle aggregation during formulation process (data not
shown). As a result, a direct 1:2 ratio of organic to aqueous phase
solution was used for nanoparticle synthesis.

Measurements of NP formulated nanoparticles using PVA
stabilizer revealed lower stability and lower particle size parameters in comparison to DMAB formulations (Table 3). At
8,800 rpm centrifugation speed, particle size and zeta potential
showed inverse trends in relations to stabilizer concentration. As
stabilizer was increased zeta potential decreased, conversely
particle size increased with increasing stabilizer concentrations.
Higher centrifugation speeds maintained similar patterns with the
exception of 0.25 and 1% PVA concentrations (Table 3).
Formulations at 0.25% showed a slight reduction in particle size,
reaching its lowest diameter at 92.467.6 nm. Also, 1% stabilizer
formulations showed a higher degree of stability with increasing
zeta potential, reaching a peak zeta potential of 211.160.5 mV
(Table 3).

Figure 5. Particle Sizing Systems NICOMP analysis of diclofenac loaded 0.1% DMAB NP formulation.
doi:10.1371/journal.pone.0087326.g005
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Table 2. Effect of DMAB stabilizer and centrifugation speed on mean particle size and zeta potential of nanoparticles.

Centrifugation speed (rpm)

Concentration (% w/v)

8,800

0.1

221.261.5

132.063.6

0.25

211.860.9

214.061.5

0.5

27.460.4

216.063.4

0.75

212.760.9

182.666.8

1

Particle aggregation

Particle aggregation

12,000

Zeta potential* (mV)

Particle size* (nm)

0.1

221.660.6

108.062.1

0.25

227.760.6

168.062.2

0.5

221.360.9

158.664.8

0.75

213.662.1

183.964.9

1

Particle aggregation

Particle aggregation

Data are reported as mean 6 SD.
*Average of triplicate measurements.
doi:10.1371/journal.pone.0087326.t002

Effects of stabilizer concentrations on diclofenac
entrapment

Nanoparticle shape and surface morphology
Morphology studies were carried out using 0.25% DMAB and
1% PVA concentrations. These stabilizer concentrations were
chosen based on zeta potential and nanoparticle stability
characteristics. The TEM images of blank and diclofenac loaded
DMAB (Fig. 7A and 7B, respectively) and PVA (Fig. 8A and 8B,
respectively) formulated NPs support the particle size data
obtained by our characterization studies performed with the
zetasizer. DMAB formulated NPs have a distinct, spherical shape
composed of a dense core with diclofenac loaded NPs showing a
slightly increased size diameter due to drug incorporation (Fig. 7B).
Drug incorporation did not affect overall particle shape.
Morphology of PVA formulated NPs show a high degree of shape
variation and aggregation in both blank NPs (Fig. 8A) and
diclofenac loaded NPs (Fig. 8B).

Amount of drug entrapment was determined by UV-spectroscopy in varying stabilizer concentrations. DMAB formulated NPs
reached peak entrapment at low w/v concentration. Entrapment
levels with DMAB reached as high as 77.363.5% and were seen at
0.1% w/v DMAB concentrations. When the concentration of
DMAB increased, a linear reduction in overall drug entrapment
and entrapment amounts was seen (Fig. 6A) (Table 4). Conversely,
as centrifugation speed was increased, slightly lower levels of drug
entrapment were obtained for each formulation. Linear regression
in overall drug entrapment percentages were still maintained
(Fig. 6B) (Table 4).
Measurements of drug entrapment utilizing PVA stabilizers
showed similar findings to DMAB formulations. Drug entrapment
levels reached 73.660.9% and 75.261.7% entrapment for PVA
formulations at 0.25 and 0.5% w/v (Table 5). When centrifugation
speed was increased, drug entrapment of diclofenac reached
80.261.2% entrapment at a lower 0.1% PVA formulation
(Table 5). Increases in centrifugation speed increased drug
entrapment at 0.1%, 0.25% and 1% PVA concentrations. Drug
entrapment efficiency reduced from 75.261.7% to 28.661.9% in
0.5% PVA formulations when speed in centrifugation was
increased (Table 5).

Stabilizer influence on in vitro diclofenac release
In vitro release studies were performed on two different stabilizer
concentrations for both DMAB and PVA formulated NPs.
Stabilizer concentrations of 0.1% and 0.25% centrifuged at
12,000 rpm were chosen based on their efficient level of drug
entrapment and best fit mean representation of particle stability of
each stabilizer group. The in vitro release of both DMAB and PVA
formulated diclofenac loaded NPs are given in Figs. 9 and 10. The

Table 3. Effect of PVA stabilizer and centrifugation speed on mean particle size and zeta potential of nanoparticles.

Centrifugation speed (rpm)

Concentration (% w/v)

8,800

12,000

Zeta potential* (mV)

Particle size* (nm)

0.1

26.762.8

103.0610.6

0.25

25.662.7

114.9612.7

0.5

24.361.1

119.2611.6

1

24.260.9

129.462.4

0.1

27.4 60.9

94.1612.6

0.25

27.062.1

92.467.6

0.5

24.962.2

113.5622.9

1

211.160.5

120.566.4

Data are reported as mean 6 SD.
*Average of triplicate measurements.
doi:10.1371/journal.pone.0087326.t003
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Figure 6. Entrapment effects of varying DMAB stabilizer concentrations. Entrapment efficiency after 8,800 rpm centrifugation of diclofenac
loaded NPs (A) and entrapment efficiency after 12,000 rpm centrifugation of diclofenac loaded NPs (B). Values are expressed as mean 6 standard
deviation.
doi:10.1371/journal.pone.0087326.g006

Table 4. Entrapment efficiency of diclofenac loaded NPs using DMAB stabilizers at varying concentration.

Centrifugation speed (rpm)

Concentration (% w/v)

Amount entrapped* (mg)

EE* (%)

8,800

0.1

34.861.7

77.363.5

0.25

30.861.6

68.463.6

0.5

27.560.2

61.160.1

1

11.260.1

24.960.1

0.1

32.460.2

71.960.4

12,000

0.25

25.660.2

56.860.4

0.5

21.960.3

48.860.1

1

16.760.1

37.260.2

Amount entrapped per 45 mg diclofenac.
EE, entrapment efficiency.
Data are reported as mean 6 SD.
*Average of triplicate measurements.
doi:10.1371/journal.pone.0087326.t004
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Table 5. Entrapment efficiency of diclofenac loaded NPs using PVA stabilizers at varying concentration.

Centrifugation speed (rpm)

Concentration (% w/v)

Amount entrapped* (mg)

EE* (%)

8,800

0.1

31.760.4

70.361.1

0.25

33.160.4

73.660.9

0.5

33.960.9

75.261.7

1

29.960.6

66.461.2

0.1

36.160.5

80.261.2

12,000

0.25

34.760.2

77.160.6

0.5

14.560.9

28.661.9

1

31.460.4

69.860.2

Amount entrapped per 45 mg diclofenac.
EE, entrapment efficiency.
Data are reported as mean 6 SD.
*Average of triplicate measurements.
doi:10.1371/journal.pone.0087326.t005

statistical comparison of the percentage drug release values
obtained with the different nanoparticle stabilizer compositions
at specific sampling times revealed significant difference (P,0.05)
in both stabilizer concentration groups. DMAB formulations at
0.1% showed an initial significant increase in drug release in
comparisons to 0.1% PVA formulations during the initial 4 hr
time frame (Fig. 9) (P,0.05). After 24 hrs, total drug release was
similar with a cumulative release of over 80% achieved for both
groups (Fig. 9). The drug release of NPs formulated with 0.25%
PVA showed a similar pattern of initial release of diclofenac in
comparison to DMAB formulation (Fig. 10). Both formulations
experienced greater than 40% release during the first hour of the
study. However, after the first initial hour, cumulative release
began to increase significantly in PVA formulated groups at each
successive time point (P,0.05). PVA formulations reached an
average cumulative release percentage of 88%, while DMAB
formulation reached an average cumulative release of 73%
(Fig. 10).

[31,32]. However, to date, reformulation characteristics of
diclofenac nanoparticles for oral delivery has yet to be extensively
examined.
In this study, diclofenac loaded PLGA NPs were formulated
following an emulsion – diffusion – evaporation technique using
DMAB or PVA as stabilizers. Stabilizers function as emulsifying
agents that can offset the surface tension between organic and
aqueous phases, thereby increasing drug solubility and nanoparticle encapsulation. Because of this understanding, a variation in
the level of stabilizer used can equate to variations in nanoparticle
characteristics during the formulation process [5,33–36]. In our
study, we formulated drug loaded NPs at varying levels of PVA
and DMAB stabilizer concentrations to elucidate the most efficient
formulation characteristics for maximum drug encapsulation,
stability and size.
A study conducted by Cetin et al. [12] demonstrated low levels
of diclofenac NP stability and entrapment efficiency when using a
EudragitHL100 and EudragitHL100 PLGA based nanoparticle
formulation with PVA as stabilizer. Consequently, they also
showed that variations in polymer concentrations did not
effectively alter NP characteristics to a measurable degree. Based
on these findings diclofenac formulated NPs appeared to offer
complications in achieving premium NP characteristics during
formulation [12]. In our study, drug loaded NPs were prepared at
varied DMAB (0.1, 0.25, 0.5, 0.75, or 1% w/v) and PVA (0.1,
0.25, 0.5, or 1% w/v) concentrations. Nanoparticle size was at its
largest when DMAB concentrations were between 0.25, 0.5, and
0.75% w/v. Consequently, zeta potential and stability of NPs were
highest when DMAB concentrations were lower (Table 2).
Surprisingly, our study demonstrated diclofenac loaded NP
particle sizes of 108 and 92.4 nm with DMAB and PVA,
respectively. Zeta potential stability measurements reached as
high as 227.760.6 mV in formulations using DMAB, and were
substantially lower in formulation utilizing PVA stabilizers
(Tables 2 and 3). These results are further supported by previously
published findings in which a EudragitHRS100 based formulation
of diclofenac was used for nanoparticle characterization. It was
found that variations in Eudragit concentrations effectively altered
drug entrapment and particle diameter characteristics for diclofenac loaded NPs. Alterations in diclofenac to Eudragit concentrations resulted in variable measurements in particle diameter,
ranging in size from 10366 to 170636 nm, which are consistent
with the size variations of 92.467.6 to 21663.4 nm found within
our study [37]. Our morphological analysis showed distinct, well

Discussion
The adverse cardiovascular, gastrointestinal, and renal side
effect caused by NSAID consumption has restricted the clinical use
of these important drugs. The main objective of our research was
to reformulate and develop a new nanoparticle formulation for
diclofenac sodium that could replace traditional capsule and tablet
oral administration and minimize or delay the onset of adverse
side effects commonly associated with NSAIDs. Nanoparticles
have been used for the development of a variety of different drug
delivery systems [1,14,16–20]. Recent studies have shown the use
of polymer based nanoparticles in the reformulation of diclofenac
for ophthalmic and colonic us with promising results [13,21–23].
Topically formulated diclofenac delivery systems have also been
used with success for the treatment of a variety of inflammatory
skin diseases [24–26]. Diclofenac delivery utilizing small lipid
nanoparticles showed promising results in the realm of drug
reformulation and enhanced drug delivery systems [27,28].
Interestingly, the use of microspheres in reformulation has
demonstrated enhanced drug entrapment and drug release of
diclofenac [29]. One study showed that the use of Eudragit and
alginate polymer systems improved drug release profiles and
enhanced the physical properties of tablet compaction [30], while
other studies have demonstrated a high degree of stability and
morphology in microsphere development with the use of PVA
PLOS ONE | www.plosone.org
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Figure 7. Morphological analysis of 0.25% DMAB formulated
NPs. Transmission electron microscopy image of empty NPs formulated
with 0.25% DMAB stabilizer (A) and transmission electron microscopy
image of diclofenac loaded NPs formulated with 0.25% DMAB stabilizer
(B).
doi:10.1371/journal.pone.0087326.g007

Figure 8. Morphological analysis of 1% PVA formulated NPs.
Transmission electron microscopy image of empty NPs formulated with
1% PVA stabilizer (A) and transmission electron microscopy image of
diclofenac loaded NPs formulated with 1% PVA stabilizer (B).
doi:10.1371/journal.pone.0087326.g008

defined diclofenac loaded NPs when formulated with 0.25%
DMAB stabilizer (Fig. 7B). The visualization of 1% PVA
formulations showed distinct NP aggregation (Fig. 8A and B).
These findings are consistent with particle properties of low zeta

potential noticed during our characterization studies performed
with the zetasizer. A more pronounced zeta potential value has a
tendency to stabilize and prevent particle aggregation [38]. It is
known that particles with a larger charge experience a much
higher degree of repulsion from other like charged particles [38].

PLOS ONE | www.plosone.org
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Figure 9. In vitro drug release study with 0.1% stabilizer concentrations. In vitro release profile of diclofenac sodium in phosphate buffer of
pH 7 from 0.1% PVA formulated NPs and 0.1% DMAB formulated NPs (mean 6 SD, n = 3, p,0.05).
doi:10.1371/journal.pone.0087326.g009

6B) or concentration (Table 4) of stabilizer used. The highest level
of entrapment reached was 77.363.5% and was seen with DMAB
concentrations of 0.1% w/v. It is important to note that stabilizing
agents are important factors in determining the entrapment
efficiency of lipophilic drugs. Stabilizers function by forming
molecular micelles through interactions between hydrophobic
portions of the stabilizers with the hydrophobic core of the NP. In
other studies, it was shown that as concentrations of DMAB
increases, entrapment of lipophilic drug increases in response [5].
Our findings have demonstrated the opposite in regards to
entrapment, suggesting that the high polarizability of diclofenac
effectively works against the micelle formation properties of
DMAB resulting in a reduction in drug entrapment as DMAB
concentrations increase.

The high degree of particle aggregation of 1% PVA formulations
are indicative of poor stability and reduced zeta potential [38,39],
which is in line with our initial findings. TEM scaling measured
particle sizes within the range reported by zetasizer analysis for
both formulations (Table 2 and 3). These findings suggest the use
of specific DMAB concentrations in effectively formulating stable
PLGA based diclofenac loaded NPs.
Entrapment efficiency is a crucial step in the characterization of
an effectively formulated drug encapsulated nanoparticle. In our
study, the result of drug encapsulation efficiencies with differing
stabilizer concentrations and centrifugation speeds is shown in
Tables 4 and 5. Our study showed high degrees of drug
encapsulation for both DMAB and PVA formulations. In DMAB
formulations, drug encapsulation followed a linear decline in the
amount of drug entrapped in relation to the amount (Figs. 6A and

Figure 10. In vitro drug release study with 0.25% stabilizer concentrations. In vitro release profile of diclofenac sodium in phosphate buffer
of pH 7 from 0.25% PVA formulated NPs and 0.25% DMAB formulated NPs (mean 6 SD, n = 3, p,0.05).
doi:10.1371/journal.pone.0087326.g010
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Measurements of entrapment efficiency in formulations utilizing
PVA as stabilizer showed similar results to those obtained with
DMAB. An entrapment efficiency of 80.261.2% was seen at PVA
concentrations of 0.1% following centrifugation at 12,000 rpm
(Table 5). Interestingly, while entrapment efficiency remained
high, zeta potential measurements remained close to zero,
indicating low levels of stability (Table 3). Two possible
explanations of our findings exist. One possibility is the presence
of residual PVA. The presence of residual PVA on the
nanoparticle surface has been found to mask charged groups
existing on the surface of PVA formulated nanoparticle [40].
Thus, residual PVA may effectively create a shield between the
nanoparticle and its surrounding medium, resulting in lower zeta
potential measurements that still maintain higher levels of
entrapment [40,41]. A second possibility is the correlation between
zeta potential and nanoparticle stability. Zeta potential measurements closer to zero represents a high degree of non-stability with
a weak surface charge surrounding the NP. It is highly possible
that NPs degrade and break during the centrifugation process, in
turn causing entrapped drug to leak from the NP into the medium.
The leakage of free drug into the medium could result in higher
levels of spectrophotometric drug detection during entrapment
studies.
Results of our in vitro study showed an increased initial
diclofenac burst release for NPs formulated with 0.1% DMAB
when compared to 0.1% PVA (Fig. 9). Inverse results were seen
with stabilizer concentrations at 0.25%. Formulations with PVA at
0.25% concentration demonstrated a marked increase in drug
release following one hour of agitation when compared to 0.25%
DMAB formulation. Drug release from nanoparticles can occur
through several means such as desorption of drug close to the
surface of the nanoparticle, diffusion through the polymer matrix,
or matrix erosion [2]. The fast release of diclofenac in 0.1%
DMAB concentrations may be due to diclofenac polarity and
increased levels of diclofenac absorbed closer to the surface of our
DMAB nanoparticles [42]. The stunted release noticed in 0.25%
DMAB formulation could be attributed to increased electrostatic
adhesion of the drug molecules to the polymeric matrix. It has
been shown that particles with larger zeta potential demonstrate
higher adhesion of drug molecules to the polymeric matrix as a
result of electrostatic adhesion [2]. It is possible that adhesion may
be taking place within these particles that may reduce diffusion of
diclofenac within the PLGA nanoparticle core after exposure to
dissolution medium [42,43].

The purpose of our study was to elucidate a novel formulation
for diclofenac sodium using polymer based nanoparticles. Our
results are based on NP formulations using two different stabilizers
at varying concentrations at two distinct centrifugation speeds. As
such, our results are limited to NP characteristics utilizing PVA
and DMAB stabilizers. It is entirely possible that the use of other
stabilizing agents could result in alterations of NP characteristics
above what has been seen in our study.
Solvents play a critical role in the determination of NP
characteristics as well. In our study, we utilized ethyl acetate as
our primary organic solvent for NP preparation. Our choice of
solvent was based on evidence seen in previous publications which
utilized ethyl acetate in conjunction with other solvents on the
determination of NP characteristics. Ethyl acetate was shown to be
most effective at creating stable NPs in conjunction with the use of
PLGA and DMAB as stabilizer [5,44]. The use of differing
solvents would alter pH characteristic of formulation medium.
Since our focus was on the salt form of diclofenac it is possible that
alteration in organic solvents could alter ionization and solubility
of diclofenac sodium, leading to differences in particle size,
stability and entrapment.

Conclusions
In summary, our findings revealed the fact that diclofenac
loaded PLGA NPs could be prepared utilizing low concentrations
of PVA and DMAB stabilizers. Formulation was achieved through
a very basic and simple evaporation - diffusion technique utilizing
ethyl acetate as organic solvent. In comparisons to previous
reports, the NPs of diclofenac developed in this study provided
adequate diclofenac entrapment levels and showed superior levels
of stability with a marked reduction in overall particle size.
Diclofenac loaded PLGA NPs could be used as an alternative to
existing oral delivery methods and aid in offsetting deleterious side
effects common to NSAID use.
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